Transgenic animals produced by homologous sequence targeting

• US 20020108136A1
• Filed: 08/09/2001
• Published: 08/08/2002
• Est. Priority Date: 03/21/1997
• Status: Abandoned Application

• Current Assignee: SRI International, Inc.
• Original Assignee: SRI International, Inc.
• Inventors: Zarling, David, Pati, Sushma
• Application Number:
  US09/927,160
• Publication Number:
  US 20020108136A1
• Time in Patent Office: Days
• US Class Current: 800/14
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4712 Cystic fibrosis
• CPC Class Codes: C07K 14/4746 p53
• CPC Class Codes: C12N 15/102 Mutagenizing nucleic acids
• CPC Class Codes: C12N 15/90 Stable introduction of foreign DNA into chromosome
• CPC Class Codes: C12N 15/902 using homologous recombination
• CPC Class Codes: C12N 15/907 in mammalian cells
• CPC Class Codes: C12N 9/1018 Carboxy- and carbamoyl transferases (2.1.3)

Abstract

The invention relates to methods and compositions for producing transgenic animals by targeted homologous recombination comprising targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a target cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence. In certain embodiments, the invention relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.

Claims

1. A non-human mammal comprising a modified endogenous gene, wherein said endogenous gene is selected from the group consisting of a gene or sequence encoding an ion-channel, a G-protein coupled receptor (GPCR), an immnunoglobulin, a growth factor, an enzyme, or a milk protein.

2. A mammal according to claim 1 wherein said mammal is a farm animal.

3. A mammal according to claim 2 wherein said farm animal is selected from the group consisting of cattle, sheep, pigs, horses and goats.

4. A mammal according to claim 1 wherein said mammal is selected from the group consisting of mice, rats, rabbits, guinea pigs, hamsters and gerbils.

5. A mammal according to claim 1 wherein said milk protein gene is a lactoglobulin gene.

6. A mammal according to claim 5 wherein said lactoglobulin gene is the α

-lactoglobulin gene or the β

-lactoglobulin gene.

7. A mammal according to claim 6 wherein said modified α

-lactoglobulin gene or β

-lactoglobulin gene does not encode any phenylalanine residues.

8. A mammal according to claim 1 wherein said endogenous gene is disrupted by deletion of at least one nucleotide.

9. A mammal according to claim 1 wherein said endogenous gene is disrupted by an insertion sequence.

10. A mammal according to claim 9 wherein said insertion sequence is a polylinker sequence.

11. A mammal according to claim 9 wherein said insertion sequence is a reporter gene.

12. A mammal according to claim 11 wherein said reporter gene is selected from the group consisting of a luciferase gene, a β

-galactosidase gene and green fluorescent protein (GFP), blue fluorescent protein (BFP), red fluorescent protein (RFP) and yellow fluorescent protein (YFP).

13. A mammal according to claim 9 wherein said insertion sequence is selected from the group consisting of a gene encoding human lysozyme, human growth hormone, human serum albumin, human globin, a human immunoglobulin, and a human enzyme.

14. A mammal according to claim 12 wherein said human enzyme is α

-1 antitrypsin.

15. A mammal according to claim 12 wherein said human enzyme is anti-thrombin III.

16. A mammal according to claim 12 wherein said human enzyme gene does not encode any phenylalanine residues.

17. A mammal according to claim 9 wherein said insertion sequence is selected from the group consisting of a human gene under control of its endogenous promoter, a modified endogenous regulatory element for an endogenous gene, a transcriptional regulation cassette and a dimerizing sequence.

18. A mammal according to claim 17 wherein said endogenous regulatory element is disrupted by deletion of at least one nucleotide.

19. A mammal according to claim 17 wherein said regulatory element is disrupted by an insertion sequence.

20. A mammal according to claim 1 wherein said enzyme is a sugar transferase enzyme.

21. A mammal according to claim 20 wherein said sugar transferase enzyme is α

-galactosyl transferase.

22. A mammal according to claim 21 wherein said α

-galactosyl transferase gene is disrupted by deletion of at least one nucleotide.

23. A mammal according to claim 21 wherein said α

-galactosyl transferase gene is disrupted by an insertion sequence.

24. A mammal according to claim 23 wherein said insertion sequence is a hormone receptor gene.

25. A mammal according to claim 23 wherein said insertion sequence is a viral receptor gene.

26. A mammal according to claim 23 wherein said insertion sequence is a G-protein coupled receptor gene.

28. A primate according to claim 27 wherein said endogenous gene is disrupted by deletion of at least one nucleotide.

29. A primate according to claim 27 wherein said endogenous gene is disrupted by an insertion sequence.

30. A primate according to claim 29 wherein said insertion sequence is a human therapeutic gene.

31. A primate according to claim 29 wherein said insertion sequence is a human antibody gene.

27. A primate comprising a modified endogenous gene.